<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04229706</url>
  </required_header>
  <id_info>
    <org_study_id>TSL-TCM-XJRPNJN-Ⅱ</org_study_id>
    <nct_id>NCT04229706</nct_id>
  </id_info>
  <brief_title>A Study of Xiangjurupining Capsule in the Treatment of Hyperplasia of Breast (Liver Stagnation and Phlegm Coagulation)</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Clinical Study on the Efficacy and Safety of Xiangjurupining Capsule in the Treatment of Hyperplasia of Breast (Liver Stagnation and Phlegm Coagulation)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tasly Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tasly Pharmaceuticals, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is to evaluate the efficacy and safety of two doses of xiangjurupining capsule in
      Hyperplastic disease of breast patients .
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is to evaluate the efficacy and safety of two doses of xiangjurupining capsule,give
      three times a day versus placebo in Hyperplastic disease of breast patients .The clinical
      phase of the study comprises a run-in period，an 3-months double-blind treatment period and a
      1-month follow-up period, resulting in 5-months overall duration of the study for each
      patient.

      Patients report their breast pain as measured using NRS scale on the subject daily diary。
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 31, 2019</start_date>
  <completion_date type="Anticipated">August 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The pain of breast</measure>
    <time_frame>up to 3 months</time_frame>
    <description>Subject reported breast pain using NRS( Numerical Rating Scale)scale on the subject daily diary..The NRS scale is a line composed of 11 points, marked with a scale of 0 to 10. The subjects rated themselves according to the most painful degree every day. The higher the score, the higher the degree of pain.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The days of pain</measure>
    <time_frame>up to 3 months</time_frame>
    <description>Subject reported breast pain as measured using NRS scale on the subject daily diary.The number of the pain days was calculated and compared with the baseline which the number of pain days in the lead-in period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The target lump</measure>
    <time_frame>3 months after treatment</time_frame>
    <description>Assess the scope ,the size and the hardness of the target lump by palpation.The doctor palpated the breast of the subjects and measured the size of the target lump with a ruler.Four quadrant method was used to record the number of the target lump's quadrants.Four level（0,2,4,6） to measure The scope,the size and the hardness of lump .the Score from 0(none) to 6(most severe).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The target lump area</measure>
    <time_frame>3 months after treatment</time_frame>
    <description>Assess the breast glandular section thickness, breast duct width and nodules of the target lump area by B-ultrasound.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>TCM syndrome scores</measure>
    <time_frame>3 months after treatment</time_frame>
    <description>Compared wth baseline,the scores of changes of TCM syndrome Evaluation at each visit .This instrument consists of two primary symptoms: breast pain, breast mass ,and four secondary symptoms.Four levels to measure severity of primary symptoms（0、2、4、6）and secondary symptoms（0、1、2、3）, respectively. Record the tongue and pulse conditions. The TCM syndrome effect calculated by nimodipine method. The final score has a range of 0 to 100. The effect of TCM syndrome from 0% (negative ) to 100% (disappear).</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Hyperplasia of Breast</condition>
  <arm_group>
    <arm_group_label>High dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>xiangjurupining capsule ,8 capsules，tid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lower dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>xiangjurupining capsule, 4 capsules,tid, xiangjurupining capsule placebo ,4 capsules，tid，po</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>xiangjurupining capsule placebo ,8 capsules，tid，po</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>xingjurupining capsule</intervention_name>
    <description>xingjurupining capsule,8 capsule,tid,3 months.</description>
    <arm_group_label>High dose group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>xiangjurupining capsule, xiangjurupining capsule placebo</intervention_name>
    <description>xiangjurupining capsule,4 capsules , and xiangjurupining capsule placebo,4 capsules,tid,3 months.</description>
    <arm_group_label>Lower dose group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>xiangjurupining capsule placebo</intervention_name>
    <description>xiangjurupining capsule,8 capsule,tid,3 months.</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Female patients aged 18-50 years.

          2. Those who meet the diagnostic criteria of breast hyperplasia and has a course of more
             than 3 months;

          3. Conform to the syndrome differentiation standard of liver depression and phlegm
             coagulation;

          4. Patients have a basic regular menstrual cycle (21-35 days) and a menstrual period (3-7
             days)

          5. BI-RADS grade 2-3

          6. NRS score ≥ 4 points in screening period

          7. The average score of NRS was ≥ 4 in the run-in period, and there was still a target
             lump in palpation

          8. Volunteer to participate in the experiment and sign the informed consent form after
             informed consent（Patients voluntarily accepted the test and gave informed consent）

        Exclusion Criteria:

          1. Patients with other breast diseases or other causes of breast pain, such as mastitis,
             breast cancer, etc.

          2. Patients with severe cardiovascular and cerebrovascular diseases, liver, kidney,
             malignant tumor, blood system diseases and mental diseases.

          3. Patients who have been confirmed with dysfunctional uterine bleeding, amenorrhea,
             polycystic ovary syndrome, menopausal syndrome and hyperprolactinemia before, still
             need to be treated by regulating hormone level.

          4. Patients with previously confirmed hypercortisolism who still need to be treated with
             bromocriptine.

          5. Those with menstrual period more than 7 days, menopause and serious irregular
             menstrual cycle.

          6. Alt, AST, ALP, TBIL, GGT are above the upper limit of normal value; serum Cr, bun are
             over normal on-line, or blood, urine routine, ECG and other examination items are
             abnormal and of clinical significance.

          7. That who pregnant or lactating women, or have a pregnant plan within the next 6 months

          8. Chinese or Western medicine was used to treat hyperplasia of mammary gland within 1
             month before the treatment and during run-in period(including external application
             medicine, acupuncture, etc.) and hormone drugs have been used within half a year
             (except for long-term oral contraceptives).

          9. Allergic constitution, known to be allergic to the ingredients of the prescription of
             the test drug

         10. History of alcohol or drug abuse.

         11. Participants in other clinical trials within 3 months before screening

         12. According to the judgment of the researchers, there are other diseases or situations
             that reduce the possibility of enrollment or complicate the enrollment, such as
             frequent changes in the working environment, which are likely to cause lost visits,
             and people with mental and behavioral disorders that cannot be based on the full
             informed consent.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hua Wang</last_name>
    <phone>13611666266</phone>
    <email>drwanhua@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jiamei Feng, MD</last_name>
    <phone>13611708021</phone>
    <email>jessie_fjm@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Baoding No.1 Hospital of TCM</name>
      <address>
        <city>Baoding</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shuxiu Fu</last_name>
      <phone>17778880872</phone>
      <email>fushuxiu@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dongfang Hospital ,Beijing University of Chinese Medicine</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dongsheng Zhu</last_name>
      <phone>13601062353</phone>
      <email>13601062353@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dongzhimen Hospital,Beijing University of Chinese Medicine</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xiaoguang Shi</last_name>
      <phone>13301119560</phone>
      <email>13301119560@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guangdong Provincial Hospital of TCM</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rui Xu</last_name>
      <phone>18903068226</phone>
      <email>Catdoctor007@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>the First Affiliated Hospital of Guangzhou University of TCM</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mei Huang</last_name>
      <phone>13318813193</phone>
      <email>huangmeiigz@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Longhua Hospital, Shanghai University of Traditional Chinese Medicine</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yuenong Qin</last_name>
      <phone>18917763372</phone>
      <email>frank_yching@aliyun.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>SHUGUANG Hospital, Shanghai University of Traditional Chinese Medicine</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>Weifang Traditional Chinese Hospital</name>
      <address>
        <city>Weifang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guolou Li</last_name>
      <phone>18606361899</phone>
      <email>cylgl@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>January 8, 2020</study_first_submitted>
  <study_first_submitted_qc>January 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2020</study_first_posted>
  <last_update_submitted>January 14, 2020</last_update_submitted>
  <last_update_submitted_qc>January 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hyperplasia of breast</keyword>
  <keyword>Xiangjurupining capsule</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

